Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena

Manali Mukherjee, David Felipe Forero, Stephanie Tran, Marie-Eve Boulay, Mylène Bertrand, Anurag Bhalla, Jayant Cherukat, Hajar Al-Hayyan, Anmar Ayoub, Spencer D. Revill, Tanvi Javkar, Katherine Radford, Melanie Kjarsgaard, Chynna Huang, Anna Dvorkin-Gheva, Kjetil Ask, Ronald Olivenstein, Nandini Dendukuri, Catherine Lemiere, Louis-Philippe Boulet, James G. Martin, Parameswaran Nair
European Respiratory Journal 2020 56: 2000117; DOI: 10.1183/13993003.00117-2020
Manali Mukherjee
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
9Supervision of this work was shared by M. Mukherjee and P. Nair, and both take overall guarantee of the manuscript
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Manali Mukherjee
David Felipe Forero
3Technology Assessment Unit, McGill University Health Centre, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David Felipe Forero
Stephanie Tran
4Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Eve Boulay
5Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mylène Bertrand
5Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anurag Bhalla
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jayant Cherukat
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hajar Al-Hayyan
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anmar Ayoub
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Spencer D. Revill
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanvi Javkar
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katherine Radford
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melanie Kjarsgaard
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chynna Huang
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Dvorkin-Gheva
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anna Dvorkin-Gheva
Kjetil Ask
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Kjetil Ask
Ronald Olivenstein
6Dept of Medicine, McGill University, Montreal, QC, Canada
7Meakins-Christie Laboratories, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nandini Dendukuri
8Centre for Outcomes Research, Department of Medicine, McGill University, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Catherine Lemiere
4Faculty of Medicine, Université de Montréal, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Louis-Philippe Boulet
5Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Québec (CRIUCPQ), Université Laval, Québec, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James G. Martin
6Dept of Medicine, McGill University, Montreal, QC, Canada
7Meakins-Christie Laboratories, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Parameswaran Nair
1Dept of Medicine, Division of Respirology, McMaster University, Hamilton, ON, Canada
2Firestone Institute for Respiratory Health, St Joseph's Healthcare, Hamilton, ON, Canada
9Supervision of this work was shared by M. Mukherjee and P. Nair, and both take overall guarantee of the manuscript
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Parameswaran Nair
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background In clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs: mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce exacerbations by ∼50–60%.

Objective To observe response to anti-IL-5 mAbs in a real-life clinical setting, and to evaluate predictors of suboptimal response.

Methods In four Canadian academic centres, predefined clinical end-points in 250 carefully characterised moderate-to-severe asthmatic patients were collected prospectively to assess response to the two anti-IL-5 mAbs. Suboptimal response was determined based on failure to reduce maintenance corticosteroid (MCS) or asthma symptoms scores (Asthma Control Questionnaire (ACQ)) or exacerbations, in addition to persistence of sputum/blood eosinophils. Worsening in suboptimal responders was assessed based on reduced lung function by 25% or increase in MCS/ACQ. A representative subset of 39 patients was evaluated for inflammatory mediators, autoantibodies and complement activation in sputum (by ELISA) and for immune-complex deposition by immunostaining formalin-fixed paraffin-embedded sputum plugs.

Results Suboptimal responses were observed in 42.8% (107 out of 250) patients treated with either mepolizumab or reslizumab. Daily prednisone requirement, sinus disease and late-onset asthma diagnoses were the strongest predictors of suboptimal response. Asthma worsened in 13.6% (34 out of 250) of these patients. The majority (79%) of them were prednisone-dependent. Presence of sputum anti-eosinophil peroxidase immunoglobulin (Ig)G was a predictor of suboptimal response to an anti-IL-5 mAb. An increase in sputum C3c (marker of complement activation) and deposition of C1q-bound/IL-5-bound IgG were observed in the sputa of those patients who worsened on therapy, suggesting an underlying autoimmune-mediated pathology.

Conclusion A significant number of patients who meet currently approved indications for anti-IL5 mAbs show suboptimal response to them in real-life clinical practice, particularly if they are on high doses of prednisone. Monitoring blood eosinophil count is not helpful to identify these patients. The concern of worsening of symptoms associated with immune-complex mediated complement activation in a small proportion of these patients highlights the relevance of recognising airway autoimmune phenomena and this requires further evaluation.

Abstract

Severe asthmatics with adult-onset asthma, sinus disease and requiring daily prednisone, are at higher risk for responding suboptimally to current doses of anti-IL-5 mAbs, with further risk of worsening on an IgG1 mAb if they have sputum autoantibodies https://bit.ly/2Ahpvsm

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • Author contributions: P. Nair and M. Mukherjee developed the concept, M. Mukherjee designed all experiments. P. Nair, J.G. Martin, C. Lemiere and L-P. Boulet recruited patients. S. Tran, M-E. Boulay, M. Bertrand, H. Al-Hayyan, J. Cherukat, M. Kjarsgaard and C. Huang collected and tabulated the data. K. Radford and M. Mukherjee performed molecular experiments. T. Javkar performed all immunostaining protocols while K. Ask, S.D. Revill and A. Ayoub did the microscopy and related validation of image analysis. A. Dvorkin-Gheva, N. Dendukuri and D.F. Forero undertook all statistical analysis. M. Mukherjee wrote the first draft. P. Nair, J.G. Martin, K. Ask, C. Lemiere, L-P. Boulet and N. Dendukuri edited and added to the development of the manuscript. All authors have read and agreed to the submitted manuscript. P. Nair and M. Mukherjee take overall guarantee of the manuscript.

  • Conflict of interest: M. Mukherjee reports grants from Canadian Institutes of Health Research and Canadian Allergy, Asthma, and Immunology Foundation, grants and personal fees from Methapharm Specialty Pharmaceuticals, and personal fees from Astrazeneca, outside the submitted work.

  • Conflict of interest: D.F. Forero has nothing to disclose.

  • Conflict of interest: S. Tran has nothing to disclose.

  • Conflict of interest: M-E. Boulay has nothing to disclose.

  • Conflict of interest: M. Bertrand has nothing to disclose.

  • Conflict of interest: A. Bhalla has nothing to disclose.

  • Conflict of interest: J. Cherukat has nothing to disclose.

  • Conflict of interest: H. Al-Hayyan has nothing to disclose.

  • Conflict of interest: A. Ayoub has nothing to disclose.

  • Conflict of interest: S.D. Revill has nothing to disclose.

  • Conflict of interest: T. Javkar has nothing to disclose.

  • Conflict of interest: K. Radford has nothing to disclose.

  • Conflict of interest: M. Kjarsgaard has nothing to disclose.

  • Conflict of interest: C. Huang has nothing to disclose.

  • Conflict of interest: A. Dvorkin-Gheva has nothing to disclose.

  • Conflict of interest: K. Ask reports grants from Canadian Pulmonary Fibrosis Foundation, Ontario Thoracic Society, Synairgen, GSK, Indalo, Unity, Avalyn, Canadian Institutes of Health Research and Synairgen, grants and personal fees from Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: R. Olivenstein has nothing to disclose.

  • Conflict of interest: N. Dendukuri has nothing to disclose.

  • Conflict of interest: C. Lemiere reports grants and personal fees for advisory board work from AstraZeneca and TEVA Innovation, personal fees for advisory board work from GlaxoSmithKline, Sanofi and Novartis, outside the submitted work.

  • Conflict of interest: L-P. Boulet has nothing to disclose.

  • Conflict of interest: J.G. Martin has nothing to disclose.

  • Conflict of interest: P. Nair reports grants and personal fees for lectures from AZ and Teva, grants from Novartis and Sanofi, grants and personal fees for consultancy from Roche, personal fees for lectures from Novartis, personal fees advisory board work from Merck and Equillium, outside the submitted work.

  • Support statement: This study was funded by a research grant awarded to P. Nair by the Canadian Institutes of Health Research. P. Nair is supported by the Frederick E. Hargreave Teva Innovation Chair in Airway Diseases. M. Mukherjee is supported by an investigator award from CIHR and Canadian Allergy, Asthma and Immunology Foundation/AllerGen NCE. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received January 20, 2020.
  • Accepted May 8, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 4 Table of Contents
European Respiratory Journal: 56 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Manali Mukherjee, David Felipe Forero, Stephanie Tran, Marie-Eve Boulay, Mylène Bertrand, Anurag Bhalla, Jayant Cherukat, Hajar Al-Hayyan, Anmar Ayoub, Spencer D. Revill, Tanvi Javkar, Katherine Radford, Melanie Kjarsgaard, Chynna Huang, Anna Dvorkin-Gheva, Kjetil Ask, Ronald Olivenstein, Nandini Dendukuri, Catherine Lemiere, Louis-Philippe Boulet, James G. Martin, Parameswaran Nair
European Respiratory Journal Oct 2020, 56 (4) 2000117; DOI: 10.1183/13993003.00117-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena
Manali Mukherjee, David Felipe Forero, Stephanie Tran, Marie-Eve Boulay, Mylène Bertrand, Anurag Bhalla, Jayant Cherukat, Hajar Al-Hayyan, Anmar Ayoub, Spencer D. Revill, Tanvi Javkar, Katherine Radford, Melanie Kjarsgaard, Chynna Huang, Anna Dvorkin-Gheva, Kjetil Ask, Ronald Olivenstein, Nandini Dendukuri, Catherine Lemiere, Louis-Philippe Boulet, James G. Martin, Parameswaran Nair
European Respiratory Journal Oct 2020, 56 (4) 2000117; DOI: 10.1183/13993003.00117-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • EmPHasis-10 as a measure of quality of life in PAH
  • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
  • Periostin and airway epithelial function in asthma
Show more Original Articles

Asthma

  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
  • Complement C3 and allergic asthma
  • Identifying asthma phenotypes based on extrapulmonary traits
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society